Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastric Bypass | 11 | 2022 | 820 | 3.290 |
Why?
|
Bone Density | 36 | 2024 | 3491 | 3.050 |
Why?
|
Osteoporosis | 14 | 2023 | 1582 | 2.510 |
Why?
|
Obesity, Morbid | 7 | 2020 | 1292 | 1.660 |
Why?
|
Absorptiometry, Photon | 18 | 2023 | 1707 | 1.470 |
Why?
|
Bone Diseases, Metabolic | 5 | 2022 | 407 | 1.450 |
Why?
|
Bariatric Surgery | 6 | 2020 | 997 | 1.420 |
Why?
|
Gastroplasty | 3 | 2020 | 153 | 1.230 |
Why?
|
Fractures, Bone | 8 | 2024 | 2041 | 1.200 |
Why?
|
Bone Remodeling | 6 | 2018 | 577 | 1.090 |
Why?
|
Osteoporosis, Postmenopausal | 4 | 2021 | 399 | 1.020 |
Why?
|
Radius | 9 | 2023 | 440 | 0.980 |
Why?
|
Postmenopause | 9 | 2021 | 2515 | 0.940 |
Why?
|
Gastrectomy | 3 | 2021 | 694 | 0.900 |
Why?
|
Bone and Bones | 11 | 2023 | 2554 | 0.880 |
Why?
|
Libido | 3 | 2020 | 123 | 0.870 |
Why?
|
Osteonecrosis | 2 | 2022 | 230 | 0.780 |
Why?
|
Bone Density Conservation Agents | 6 | 2022 | 791 | 0.770 |
Why?
|
Goserelin | 3 | 2020 | 126 | 0.730 |
Why?
|
Teriparatide | 2 | 2014 | 225 | 0.700 |
Why?
|
Testosterone | 5 | 2020 | 2494 | 0.680 |
Why?
|
Adipose Tissue | 5 | 2021 | 3312 | 0.670 |
Why?
|
Histamine H2 Antagonists | 2 | 2011 | 168 | 0.610 |
Why?
|
Magnetite Nanoparticles | 4 | 2024 | 309 | 0.570 |
Why?
|
Osteoporotic Fractures | 4 | 2024 | 415 | 0.560 |
Why?
|
Bone Resorption | 3 | 2018 | 717 | 0.550 |
Why?
|
Tibia | 8 | 2023 | 1062 | 0.550 |
Why?
|
Bone Marrow | 2 | 2016 | 2921 | 0.530 |
Why?
|
Body Composition | 9 | 2019 | 2439 | 0.510 |
Why?
|
Eunuchism | 1 | 2016 | 19 | 0.510 |
Why?
|
Bone Diseases | 1 | 2019 | 411 | 0.510 |
Why?
|
Insulin Resistance | 3 | 2020 | 3985 | 0.500 |
Why?
|
Subcutaneous Fat | 2 | 2017 | 402 | 0.480 |
Why?
|
Proton Pump Inhibitors | 2 | 2011 | 553 | 0.460 |
Why?
|
Intra-Abdominal Fat | 2 | 2017 | 623 | 0.430 |
Why?
|
Ferric Compounds | 4 | 2020 | 368 | 0.410 |
Why?
|
Adiposity | 2 | 2020 | 1890 | 0.410 |
Why?
|
Parathyroid Hormone | 4 | 2016 | 1789 | 0.410 |
Why?
|
Magnetics | 4 | 2021 | 585 | 0.410 |
Why?
|
Pelvic Bones | 3 | 2020 | 274 | 0.410 |
Why?
|
Tomography, X-Ray Computed | 10 | 2024 | 20659 | 0.400 |
Why?
|
Femur Neck | 3 | 2024 | 316 | 0.380 |
Why?
|
Obesity | 8 | 2023 | 13076 | 0.370 |
Why?
|
Intestines | 1 | 2020 | 1906 | 0.360 |
Why?
|
Bone Morphogenetic Proteins | 2 | 2012 | 844 | 0.330 |
Why?
|
Energy Metabolism | 1 | 2020 | 2892 | 0.310 |
Why?
|
Middle Aged | 41 | 2024 | 223009 | 0.280 |
Why?
|
Pandemics | 4 | 2022 | 8703 | 0.270 |
Why?
|
Humans | 75 | 2024 | 765968 | 0.260 |
Why?
|
Diagnostic Imaging | 5 | 2020 | 3529 | 0.250 |
Why?
|
Body Mass Index | 4 | 2019 | 13039 | 0.250 |
Why?
|
Spine | 3 | 2018 | 1128 | 0.240 |
Why?
|
Delivery of Health Care | 3 | 2023 | 5370 | 0.240 |
Why?
|
Hip | 2 | 2017 | 249 | 0.230 |
Why?
|
Oxytocin | 2 | 2020 | 404 | 0.230 |
Why?
|
Male | 40 | 2024 | 363698 | 0.230 |
Why?
|
Estradiol | 4 | 2017 | 1947 | 0.230 |
Why?
|
Female | 46 | 2024 | 396112 | 0.220 |
Why?
|
Hip Fractures | 3 | 2018 | 997 | 0.220 |
Why?
|
Lumbar Vertebrae | 4 | 2022 | 1873 | 0.220 |
Why?
|
Femur | 2 | 2024 | 1310 | 0.210 |
Why?
|
Medicare | 2 | 2019 | 6823 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
Cell Tracking | 2 | 2021 | 139 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
Propensity Score | 3 | 2020 | 1968 | 0.200 |
Why?
|
Peptide YY | 1 | 2022 | 135 | 0.190 |
Why?
|
Fanconi Syndrome | 1 | 2022 | 35 | 0.190 |
Why?
|
Nanomedicine | 1 | 2024 | 286 | 0.190 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 3401 | 0.190 |
Why?
|
Aging | 1 | 2020 | 8731 | 0.180 |
Why?
|
Practice Guidelines as Topic | 3 | 2013 | 7425 | 0.180 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2015 | 12240 | 0.180 |
Why?
|
Risk Assessment | 4 | 2024 | 24282 | 0.180 |
Why?
|
Weight Loss | 3 | 2019 | 2710 | 0.180 |
Why?
|
Adult | 29 | 2021 | 223044 | 0.180 |
Why?
|
Hypopituitarism | 2 | 2020 | 254 | 0.170 |
Why?
|
Postoperative Complications | 2 | 2020 | 15747 | 0.170 |
Why?
|
Penile Erection | 1 | 2020 | 100 | 0.170 |
Why?
|
Diabetes Insipidus, Neurogenic | 1 | 2020 | 20 | 0.170 |
Why?
|
X-Ray Microtomography | 1 | 2022 | 454 | 0.170 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2024 | 3446 | 0.170 |
Why?
|
Anti-Mullerian Hormone | 1 | 2022 | 420 | 0.160 |
Why?
|
Anorexia Nervosa | 2 | 2019 | 1328 | 0.160 |
Why?
|
Aged | 21 | 2024 | 171117 | 0.160 |
Why?
|
Gels | 1 | 2020 | 419 | 0.160 |
Why?
|
Muscle Strength | 2 | 2013 | 637 | 0.160 |
Why?
|
Body Fat Distribution | 1 | 2020 | 246 | 0.160 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 682 | 0.150 |
Why?
|
Risk Factors | 12 | 2024 | 74840 | 0.150 |
Why?
|
Models, Animal | 2 | 2016 | 2120 | 0.150 |
Why?
|
Congresses as Topic | 2 | 2013 | 811 | 0.150 |
Why?
|
Fractures, Spontaneous | 1 | 2020 | 230 | 0.150 |
Why?
|
Vasopressins | 1 | 2020 | 359 | 0.150 |
Why?
|
Computer Simulation | 1 | 2012 | 6255 | 0.150 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 715 | 0.150 |
Why?
|
Diphosphonates | 2 | 2022 | 625 | 0.150 |
Why?
|
Thrombophilia | 1 | 2020 | 308 | 0.140 |
Why?
|
Central Cord Syndrome | 1 | 2016 | 5 | 0.140 |
Why?
|
Unnecessary Procedures | 1 | 2020 | 416 | 0.130 |
Why?
|
Mass Screening | 1 | 2012 | 5446 | 0.130 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 415 | 0.130 |
Why?
|
United States | 14 | 2024 | 72903 | 0.130 |
Why?
|
Hydroxycholecalciferols | 1 | 2015 | 44 | 0.130 |
Why?
|
Galactose | 1 | 2017 | 299 | 0.120 |
Why?
|
Aerosols | 1 | 2018 | 633 | 0.120 |
Why?
|
Dextrans | 1 | 2017 | 571 | 0.120 |
Why?
|
Administration, Inhalation | 1 | 2018 | 1154 | 0.120 |
Why?
|
Vitamin D Deficiency | 2 | 2021 | 1348 | 0.120 |
Why?
|
Contrast Media | 3 | 2018 | 5329 | 0.120 |
Why?
|
Anemia, Sickle Cell | 1 | 2023 | 1067 | 0.120 |
Why?
|
Societies, Medical | 3 | 2024 | 3956 | 0.120 |
Why?
|
Treatment Outcome | 7 | 2020 | 65188 | 0.120 |
Why?
|
Algorithms | 3 | 2024 | 14071 | 0.120 |
Why?
|
Acromegaly | 1 | 2017 | 316 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10729 | 0.110 |
Why?
|
Cross-Sectional Studies | 6 | 2020 | 26318 | 0.110 |
Why?
|
Rare Diseases | 1 | 2019 | 635 | 0.110 |
Why?
|
Porosity | 1 | 2014 | 347 | 0.110 |
Why?
|
Menopause | 1 | 2022 | 1659 | 0.110 |
Why?
|
Glycosylation | 1 | 2017 | 1100 | 0.110 |
Why?
|
Tibial Fractures | 1 | 2017 | 276 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 1 | 2020 | 1206 | 0.110 |
Why?
|
Postprandial Period | 1 | 2015 | 319 | 0.110 |
Why?
|
Home Care Services | 1 | 2020 | 660 | 0.110 |
Why?
|
Abdominal Fat | 1 | 2015 | 217 | 0.100 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 1078 | 0.100 |
Why?
|
Case-Control Studies | 3 | 2015 | 22223 | 0.100 |
Why?
|
Hormones | 1 | 2016 | 863 | 0.100 |
Why?
|
Health Resources | 1 | 2019 | 949 | 0.100 |
Why?
|
Patient Admission | 2 | 2019 | 1365 | 0.100 |
Why?
|
Bed Rest | 1 | 2012 | 82 | 0.100 |
Why?
|
Vitamin D | 3 | 2021 | 3272 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4850 | 0.100 |
Why?
|
Radius Fractures | 1 | 2017 | 516 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1880 | 0.090 |
Why?
|
Mice, Inbred C57BL | 2 | 2022 | 22332 | 0.090 |
Why?
|
Phantoms, Imaging | 3 | 2019 | 2475 | 0.090 |
Why?
|
Animals | 10 | 2024 | 168764 | 0.090 |
Why?
|
Procollagen | 1 | 2011 | 189 | 0.090 |
Why?
|
Incidence | 3 | 2019 | 21480 | 0.090 |
Why?
|
Longitudinal Studies | 4 | 2023 | 14751 | 0.090 |
Why?
|
Time Factors | 5 | 2024 | 40065 | 0.090 |
Why?
|
Osteocalcin | 1 | 2011 | 271 | 0.090 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2016 | 504 | 0.090 |
Why?
|
Anti-Ulcer Agents | 1 | 2011 | 112 | 0.090 |
Why?
|
Young Adult | 10 | 2023 | 59889 | 0.090 |
Why?
|
Molecular Imaging | 1 | 2017 | 822 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6309 | 0.090 |
Why?
|
Polysaccharides | 1 | 2017 | 1016 | 0.090 |
Why?
|
Cell Count | 1 | 2014 | 1823 | 0.080 |
Why?
|
Recurrence | 2 | 2020 | 8501 | 0.080 |
Why?
|
Estrogens | 1 | 2017 | 1529 | 0.080 |
Why?
|
Advisory Committees | 2 | 2024 | 796 | 0.080 |
Why?
|
Pharmaceutical Preparations | 1 | 2018 | 1084 | 0.080 |
Why?
|
Pilot Projects | 2 | 2020 | 8733 | 0.080 |
Why?
|
Prospective Studies | 5 | 2022 | 54802 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39193 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1946 | 0.080 |
Why?
|
Disease Management | 1 | 2020 | 2535 | 0.080 |
Why?
|
Vision, Low | 1 | 2011 | 162 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6499 | 0.080 |
Why?
|
Calcium | 3 | 2012 | 5767 | 0.080 |
Why?
|
Nephritis | 1 | 2009 | 146 | 0.080 |
Why?
|
Dietary Supplements | 1 | 2021 | 3425 | 0.080 |
Why?
|
Genetic Markers | 2 | 2012 | 2601 | 0.080 |
Why?
|
Fasting | 1 | 2014 | 1606 | 0.080 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1811 | 0.070 |
Why?
|
Neutrophils | 1 | 2021 | 3776 | 0.070 |
Why?
|
Neoplasms | 3 | 2023 | 22340 | 0.070 |
Why?
|
Collagen Type I | 1 | 2011 | 615 | 0.070 |
Why?
|
Hip Joint | 1 | 2014 | 1000 | 0.070 |
Why?
|
Calcinosis | 1 | 2016 | 1479 | 0.070 |
Why?
|
Choroidal Neovascularization | 1 | 2011 | 360 | 0.070 |
Why?
|
Body Weight | 2 | 2016 | 4622 | 0.070 |
Why?
|
Blindness | 1 | 2011 | 586 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9338 | 0.070 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 3672 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2020 | 59489 | 0.070 |
Why?
|
Cyclic AMP | 1 | 2010 | 1467 | 0.070 |
Why?
|
Gastrointestinal Agents | 1 | 2011 | 510 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2020 | 12437 | 0.060 |
Why?
|
Cholesterol | 1 | 2015 | 2898 | 0.060 |
Why?
|
Canada | 1 | 2011 | 2119 | 0.060 |
Why?
|
Premenopause | 2 | 2022 | 1037 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12509 | 0.060 |
Why?
|
Cell Lineage | 1 | 2014 | 2573 | 0.060 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 1224 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2017 | 4528 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2056 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4628 | 0.060 |
Why?
|
Cohort Studies | 5 | 2021 | 41649 | 0.060 |
Why?
|
Spinal Fractures | 1 | 2011 | 703 | 0.060 |
Why?
|
Bone Matrix | 1 | 2024 | 126 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2012 | 2900 | 0.060 |
Why?
|
Europe | 1 | 2011 | 3423 | 0.060 |
Why?
|
Medication Adherence | 1 | 2016 | 2192 | 0.060 |
Why?
|
Macular Degeneration | 1 | 2011 | 1014 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3807 | 0.050 |
Why?
|
Mice | 5 | 2022 | 81819 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15652 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2015 | 3850 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4209 | 0.050 |
Why?
|
Spectrum Analysis, Raman | 1 | 2024 | 252 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3105 | 0.050 |
Why?
|
Mexican Americans | 1 | 2003 | 165 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2243 | 0.050 |
Why?
|
Sickness Impact Profile | 1 | 2003 | 297 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 5189 | 0.050 |
Why?
|
Aromatase Inhibitors | 2 | 2017 | 518 | 0.050 |
Why?
|
Tooth Extraction | 1 | 2022 | 225 | 0.050 |
Why?
|
Tissue Distribution | 2 | 2016 | 2266 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2024 | 81514 | 0.050 |
Why?
|
Arginine | 1 | 2024 | 933 | 0.050 |
Why?
|
Bicarbonates | 1 | 2022 | 293 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4778 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 2016 | 3213 | 0.040 |
Why?
|
Patient Compliance | 1 | 2010 | 2692 | 0.040 |
Why?
|
Lysine | 1 | 2024 | 991 | 0.040 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 7875 | 0.040 |
Why?
|
Blood Glucose | 1 | 2014 | 6424 | 0.040 |
Why?
|
Alendronate | 1 | 2021 | 174 | 0.040 |
Why?
|
Sex Factors | 2 | 2017 | 10603 | 0.040 |
Why?
|
Glioblastoma | 1 | 2015 | 3459 | 0.040 |
Why?
|
Vision, Ocular | 1 | 2003 | 457 | 0.040 |
Why?
|
Peptides | 1 | 2011 | 4331 | 0.040 |
Why?
|
Odds Ratio | 1 | 2011 | 9649 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2011 | 5125 | 0.040 |
Why?
|
Insurance Claim Review | 2 | 2016 | 746 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5891 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2020 | 9071 | 0.040 |
Why?
|
Durapatite | 1 | 2019 | 166 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 2020 | 314 | 0.040 |
Why?
|
Age of Onset | 1 | 2024 | 3344 | 0.030 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 2159 | 0.030 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.030 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2018 | 140 | 0.030 |
Why?
|
Spin Labels | 1 | 2018 | 334 | 0.030 |
Why?
|
Perfusion Imaging | 1 | 2018 | 193 | 0.030 |
Why?
|
Fertility Agents, Female | 1 | 2017 | 101 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2014 | 10261 | 0.030 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2017 | 134 | 0.030 |
Why?
|
Calcium, Dietary | 1 | 2019 | 526 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2018 | 210 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1709 | 0.030 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2017 | 274 | 0.030 |
Why?
|
Laminectomy | 1 | 2016 | 226 | 0.030 |
Why?
|
Research Design | 1 | 2011 | 6209 | 0.030 |
Why?
|
Leuprolide | 1 | 2017 | 312 | 0.030 |
Why?
|
Rats, Inbred F344 | 1 | 2016 | 822 | 0.030 |
Why?
|
Carbocyanines | 1 | 2015 | 177 | 0.030 |
Why?
|
Adolescent | 5 | 2023 | 88835 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9249 | 0.030 |
Why?
|
Hydrodynamics | 1 | 2015 | 163 | 0.030 |
Why?
|
Metal Nanoparticles | 1 | 2018 | 403 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 714 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2024 | 2207 | 0.030 |
Why?
|
Optics and Photonics | 1 | 2015 | 305 | 0.030 |
Why?
|
Psychometrics | 1 | 2003 | 3062 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 684 | 0.030 |
Why?
|
Women's Health | 1 | 2022 | 2084 | 0.030 |
Why?
|
Angiography | 1 | 2018 | 1581 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2017 | 638 | 0.020 |
Why?
|
Head-Down Tilt | 1 | 2012 | 67 | 0.020 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2012 | 110 | 0.020 |
Why?
|
Eating | 1 | 2019 | 1540 | 0.020 |
Why?
|
Postural Balance | 1 | 2016 | 637 | 0.020 |
Why?
|
Equipment Design | 1 | 2020 | 3481 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2016 | 1072 | 0.020 |
Why?
|
Finite Element Analysis | 1 | 2013 | 440 | 0.020 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2017 | 1133 | 0.020 |
Why?
|
Phosphorus | 1 | 2012 | 337 | 0.020 |
Why?
|
Weight-Bearing | 1 | 2013 | 529 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2936 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2016 | 974 | 0.020 |
Why?
|
Community Pharmacy Services | 1 | 2009 | 51 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1279 | 0.020 |
Why?
|
Nanotechnology | 1 | 2015 | 703 | 0.020 |
Why?
|
Databases, Factual | 2 | 2019 | 8067 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2015 | 1188 | 0.020 |
Why?
|
Body Size | 1 | 2012 | 459 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3426 | 0.020 |
Why?
|
Accidental Falls | 1 | 2016 | 1078 | 0.020 |
Why?
|
Temperature | 1 | 2015 | 2226 | 0.020 |
Why?
|
Physical Fitness | 1 | 2012 | 742 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2229 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2012 | 1195 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3413 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2116 | 0.010 |
Why?
|
Nanoparticles | 1 | 2016 | 1964 | 0.010 |
Why?
|
Administration, Oral | 1 | 2012 | 4015 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2009 | 1668 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 14652 | 0.010 |
Why?
|
Los Angeles | 1 | 2003 | 244 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15842 | 0.010 |
Why?
|
Visual Acuity | 1 | 2011 | 2708 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12976 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18380 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2009 | 2778 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 8923 | 0.010 |
Why?
|
Insurance, Health | 1 | 2009 | 2521 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11083 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2015 | 9373 | 0.010 |
Why?
|
Vision Disorders | 1 | 2003 | 1087 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2009 | 4270 | 0.010 |
Why?
|
Child | 1 | 2022 | 80564 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2003 | 2415 | 0.010 |
Why?
|
Language | 1 | 2003 | 1550 | 0.010 |
Why?
|
Hospitalization | 1 | 2009 | 10808 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36532 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20124 | 0.000 |
Why?
|